INTRODUCTION
Platelet activating factor (PAF)1 was identified nearly 10 yr ago (1) , and since then, the role of PAF in mediating various acute allergic and inflammatory reactions has been receiving an ever increasing amount ofexperimental support (2, 3) . Recently, direct structure-proof analyses of PAF released from antigen-stimulated immunoglobulin (Ig)E-sensitized rabbit basophils have demonstrated that PAF is an acetyl glyceryl ether phosphorylcholine (AGEPC, 1-O-hexadecyl/octadecyl-2-acetyl-sn-glyceryl-3-phosphorylcholine) (4) . The demonstration ofPAF synthesis by a variety ofinflammatory cells (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) has prompted studies to elucidate its role as an inflammatory mediator in man with particular interest focusing on the stimulation of human platelets. However, widely diverse results have been reported 1 Abbreviations used in this paper: AGEPC, acetyl glyceryl ether phosphorylcholine, 1-0-hexadecyl/octadecyl-2-acetyl-sn-glyceryl-3-phosphorylcholine; CPCK, creatine phosphate/creatine kinase; lyso-GEPC, 1-0-hexadecyl/octadecyl-sn-glyceryl-3-phosphorylcholine; PAF, platelet activating factor; PGI2, prostacyclin; PRP, platelet-rich plasma.
J. Clin. Invest. X The American Society for Clinical Investiga for washed human platelets ranging from the inability of PAF to initiate human platelet aggregation and/or secretion to the ability of PAF to induce significant platelet secretion (10, 12, (15) (16) (17) (18) . In view ofthe preceding observations, we have undertaken studies to answer the question of whether or not chemically pure AGEPC, a synthetic PAF, can initiate human platelet aggregation and secretion.
METHODS
Animals. Randomly bred, male and female California rabbits were obtained from the Penn Acres Ranch, Wimberly, Tex.
AGEPC preparation. Synthesis and chemical characterization of AGEPC and lyso-GEPC (1-0-hexadecyl/octadecylsn-glyceryl-3-phosphorylcholine) have been described (19 Anticoagulated blood was immediately centrifuged at room temperature to prepare human or rabbit PRP, 500 g for 10 min or 750 g for 15 min, respectively. The upper one-half of the PRP was removed (350,000-500,000 platelets/mm3) and to each 1 ml of PRP, 1 20 ,uM) was inactive. AGEPC also induced platelet aggregation and secretion in rabbit PRP with irreversible aggregation at 20 nM AGEPC (Fig. IB) .
The AGEPC-induced dose-response aggregation patterns in human PRP from individual blood donors varied slightly. However, the initial aggregation pattern of PRP at a given AGEPC concentration always decreased with time after PRP preparation (Fig. 2) stimulation of freshly prepared PRP with appropriate concentrations of AGEPC (usually 100-10 nM) induced similar biphasic aggregation responses. In contrast to human PRP, rabbit PRP remained fully responsive to AGEPC stimulation up to 4 h after preparation and biphasic aggregation patterns were never observed.
The second phase ofAGEPC-induced biphasic platelet aggregation was eliminated by the presence of indomethacin or CPCK. Additionally, in freshly prepared human PRP, indomethacin or CPCK prevented the irreversible aggregation response at 0.2 ,uM AGEPC without affecting platelet secretion (Fig. 3) ; at higher AGEPC concentrations (2 ,uM), indomethacin or CPCK had no effect on irreversible aggregation responses or on platelet secretion. PGI2 inhibited both aggregation and secretion at all AGEPC concentrations. EDTA or EGTA prevented AGEPC-induced platelet aggregation in human and rabbit PRP with no effect on the platelet release reaction in human PRP but with reduction of secretion in rabbit PRP.
DISCUSSION
Several possible explanations could account for the previous discrepancies and often conflicting observations with respect to PAF-induced stimulation of human platelets (10, 12, (15) (16) (17) (18) . First, either crude or partially purified PAF with possible contaminants was used in contrast to the highly purified synthetic AGEPC employed here. Second, other investigators have employed washed human platelets prepared by different procedures and/or different conditions for effecting platelet stimulation. In contrast, we have used freshly prepared human PRP. The observation that human platelet responsiveness to AGEPC decreases with time after preparation (Fig. 2) whereas rabbit platelets were stable. Second, in PRP, human platelets were less sensitive to AGEPC stimulation than rabbit platelets. These differences could be explained either by the relative instability of human platelets or alternatively, human plasma might degrade or inactivate AGEPC more rapidly than rabbit plasma.
Indeed, washed rabbit platelets (19) are approximately 100 times more sensitive to AGEPC stimulation than is rabbit PRP probably because of plasma inactivators (22 
